SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Aardvark Therapeutics, Inc. (AARD) News

Follow Aardvark Therapeutics, Inc. (AARD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol AARD Asset equity Sector Markets 90 days 5 Last 1.33 Updated Oct 22, 2026, 08:25 PM UTC Open live news feed Open AARD chart & news
M FDA Lifts Clinical Hold on Aardvark Therapeutics’ ARD-101 Aardvark Therapeutics said the FDA lifted the clinical hold on ARD-101, allowing clinical development for hyperphagia in Prader-Willi Syndrome to potentially resume. REGULATION | Oct 22, 2026, 08:25 PM UTC L Aardvark Therapeutics Price Target Maintained With a $6.00/Share by RBC Capital Ratings actions from Benzinga NEWS | Sep 24, 2026, 01:37 PM UTC L AARD - Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith AARD - Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith EQUITY | Aug 26, 2026, 05:31 PM UTC L AARD - Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Act AARD - Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action EQUITY | Aug 24, 2026, 01:06 PM UTC L AARD - LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, s AARD - LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation REGULATION | Aug 20, 2026, 06:34 PM UTC L AARD - Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action AARD - Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action EQUITY | Aug 14, 2026, 11:49 PM UTC L Aardvark Therapeutics Q2 EPS Beats Estimate Aardvark Therapeutics reports Q2 EPS of $(0.66), beating the $(0.91) estimate EARNINGS | Aug 11, 2026, 08:55 PM UTC L AARD Reports Q2 2026 Financial Results Aardvark Therapeutics reports second quarter 2026 financial results and provides business updates EARNINGS | Aug 11, 2026, 08:53 PM UTC L AARD - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS AARD - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS EQUITY | Jun 25, 2026, 01:01 PM UTC